Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
NCT07067268
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
76
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Cancinoma (NPC)
Interventions
DRUG:
Adjuvant therapy
Sponsor
Fudan University